

Organizing committee

Dr. Vicente Alonso
Hospital Universitario Miguel Servet, Zaragoza

Dr. Jorge Aparicio
Hospital Universitari i Politècnic La Fe, Valencia

Dr. Juan Ramón Ayuso
Hospital Clínic, Barcelona

Dr. Jaume Capdevila
Hospital Universitari Vall d'Hebron, Barcelona

Dr. Laura Cerezo
Hospital Universitario de La Princesa, Madrid

Dr. Jaime Feliu
Hospital Universitario La Paz, Madrid

Dr. Carlos Fernández Martos
Fundación Instituto Valenciano de Oncología, Valencia

Dra. Rocío García Carbonero
Hospital Universitario 12 de Octubre, Madrid

Dr. Xabier García de Albéniz
RTI-Health Solutions, Barcelona

Dr. Fernando López Campos
Hospital Universitario Ramón y Cajal, Madrid

Dr. Marta Martín Richard
Hospital de la Santa Creu i Sant Pau, Barcelona

Dr. Joan Maurel
Hospital Clínic, Barcelona

Dr. Manel Pera
Hospital del Mar, Barcelona

Dr. Anna Reig
Hospital del Mar, Barcelona

Dr. Javier Suarez
Complejo Universitario de Navarra, Pamplona

Scientific committee

Dr. Salah-Eddin Al-Batran
Institute of Clinical Cancer Research and Krankenhaus, Frankfurt

Dr. Vicente Alonso
Hospital Universitario Miguel Servet, Zaragoza

Dr. Jorge Aparicio
Hospital Universitari i Politècnic La Fe, Valencia

Dr. Jaume Capdevila
Hospital Universitari Vall d'Hebron, Barcelona

Dr. Andrea Cercek
Memorial Sloan Kettering Cancer Centre, New York

Dr. Laura Cerezo
Hospital Universitario de La Princesa, Madrid

Dr. Laura Dawson
Princess Margaret Cancer Centre, Toronto

Dra. Cathy Eng
MD Anderson Cancer Center, Houston, Texas

Dr. Carlos Fernández-Martos
Instituto Valenciano de Oncología, Valencia

Dr. Remond Fijneman
The Netherlands Cancer Institute, Amsterdam

Dr. Javier Gallego
Hospital Universitario, Elche

Dr. Julio García-Aguilar
Memorial Sloan Kettering Cancer Centre, New York

Dra. Rocío García-Carbonero
Hospital Universitario 12 de Octubre, Madrid

Dr. Xabier García de Albéniz
RTI-Health Solutions, Barcelona

Dr. Suzanne Gisbertz
Academisch Medisch Centrum, Amsterdam

Dr. Robert Glynne-Jones
Mount Vernon Centre, Northwood

Dr. Ajay Goel
Baylor institute, Dallas

Dr. Manuel Hidalgo
Beth Israel Deaconess Medical Center, Boston

Dr. Jim Kaye
RTI-Health Solutions, Massachusetts

Dra. Ángela Lamarca
The Christie's, Manchester

Dra. Marta Martín-Richard
Hospital de la Santa Creu i Sant Pau, Barcelona

Dr. Manel Pera
Hospital del Mar, Barcelona

Prof. Russell Petty
University of Dundee, Scotland

Dr. Anna Reig
Hospital del Mar, Barcelona

Dr. Geertjan van Tienhoven
Academisch Medisch Centrum, Amsterdam

Organized by:



www.gemcad.es

Technical Secretariat:



Secretari Coloma 64-68, Esc.B, entlo. 5ª
08024 Barcelona
Tel. 93 43 44 412
Fax 932 531 168
secretaria@gemcad.es
www.mfar.es

Venue:

Hotel NH Eurobuilding
Roma meeting room
Calle de Padre Damián, 23
28036 Madrid

Registration fee: 363€ (taxes included)
Access to scientific sessions

Payment: by bank transfer to GEMCAD account:
Es70 2100 0827 12 0200707318.

To complete your registration please send your personal details (full name, hospital, service, telephone and email) to GEMCAD Technical Secretariat together with the proof of payment.

Under the auspice of:



Sponsors:

Silver



Bronze



Bristol-Myers Squibb



SANOFI



Updates in the multidisciplinary treatment of digestive tumors

madrid 4th-5th April 2019

SCIENTIFIC PROGRAM
Hotel NH Eurobuilding
Roma meeting room

VII GEMCAD Symposium

Organized by:



GRUPO ESPAÑOL MULTIDISCIPLINAR
EN CÁNCER DIGESTIVO

THURSDAY 4TH APRIL

- 16.00-18.00h** **TABLE I: Point-Counterpoint session. How to analyze and interpret randomized clinical trials: intention-to-treat vs. per-protocol analysis**
Chair:
Dr. Xabier García de Albéniz. RTI-Health Solutions, Barcelona
- 16.00-16.40h Pros of the intention-to-treat analysis. When and why not to use a per-protocol analysis
Dr. Jim Kaye. RTI-Health Solutions, Massachusetts
- 16.40-17.20h Pros of the per-protocol analysis. When and why not to use an intention-to-treat analysis
Dr. Xabier García de Albéniz. RTI-Health Solutions, Barcelona
- 17.20-18.00h Discussion
- 18.00-18.30h** **TABLE II: Radiotherapy**
Chair:
Dr. Laura Cerezo. Hospital Universitario de La Princesa, Madrid
- 18.00-18.20h Integration of SBRT in the treatment algorithm of gastrointestinal tumors (evidence based indications in liver metastases, pancreatic cancer and other tumors)
Dr. Laura Dawson. Princess Margaret Cancer Centre, Toronto
- 18.20-18.30h Discussion
- 18.30-20.00h **GEMCAD GENERAL ASSEMBLY**

FRIDAY 5TH APRIL

- 08.55-09.00h **Welcome**
Dr. Carlos Fernández Martos. Instituto Valenciano de Oncología, Valencia
- 09.00-10.30h** **TABLE III: Esophagus and gastric cancer**
Chairs:
Dr. Marta Martín-Richard. Hospital de la Santa Creu i Sant Pau, Barcelona
Dr. Manel Pera. Hospital del Mar, Barcelona
- 09.00-09.20h **Molecular subgroups in esophagus adenocarcinoma**
Prof. Russell Petty. University of Dundee, Scotland
- 09.20-09.40h **Minimally invasive surgery for GEJ and gastric cancer**
Dr. Suzanne Gisbertz. Academisch Medisch Centrum, Amsterdam
- 09.40-10.00h **Other criteria to take into account when a perioperative treatment is proposed**
Dr. Salah-Eddin Al-Batran. Institute of Clinical Cancer Research and Krankenhaus, Frankfurt
- 10.00-10.30h Discussion
- 10.30-12.00h** **TABLE IV: Pancreatic and biliary ducts cancer**
Chairs:
Dr. Rocío García-Carbonero. Hospital Universitario 12 de Octubre, Madrid
Dr. Anna Reig. Hospital del Mar, Barcelona
- 10.30-10.50h **New horizons for precision medicine in biliary tract cancers**
Dr. Ángela Lamarca. The Christie's, Manchester
- 10.50-11.10h **Resectable pancreatic cancer: adjuvant and neoadjuvant strategies**
Dr. Geertjan van Tienhoven. Academisch Medisch Centrum, Amsterdam
- 11.10-11.30h **The genomic landscape of pancreatic cancer – potential clinical implications**
Dr. Manuel Hidalgo. Beth Israel Deaconess Medical Center, Boston
- 11.30-12.00h Discussion
- 12.00-13.00h **Lunch**

FRIDAY 5TH APRIL

- 13.00-14.30h** **TABLE V: Colon cancer**
Chairs:
Dr. Vicente Alonso. Hospital Universitario Miguel Servet, Zaragoza
Dr. Jorge Aparicio. Hospital Universitari i Politècnic La Fe, Valencia
- 13.00-13.20h **Clinical application of liquid biopsy ctDNA detection in metastatic colorectal cancer. Potential implementation in stage III**
Dr. Remond Fijneman. The Netherlands Cancer Institute, Amsterdam
- 13.20-13.40h **New blood biomarkers in advanced metastatic colorectal cancer**
Dr. Ajay Goel. Baylor institute, Dallas
- 13.40-14.00h **Immunotherapy in metastatic MSS colorectal cancer patients. A rational for select the best patients with optimal combination**
Dr. Cathy Eng. MD Anderson Cancer Center, Houston, Texas
- 14.00-14.30h Discussion
- 14.30 - 16.05h** **TABLE VI: Rectal cancer**
Chairs:
Dr. Jaume Capdevila. Hospital Universitari Vall d'Hebron, Barcelona
Dr. Javier Gallego. Hospital Universitario, Elche
- 14.30-14.50h **Treatment of micrometastatic disease in locally advanced rectal cancer Induction or adjuvant for c stage II and III rectal cancer**
Dr. Andrea Cercek. Memorial Sloan Kettering Cancer Centre, New York
- 14.50-15.10h **Adjuvant Just for ypT stage III or nobody?**
Dr. Robert Glynn-Jones. Mount Vernon Centre, Northwood
- 15.10-15.30h **Clinical complete response as a new primary endpoint in locally advanced rectal cancer**
Dr. Julio García-Aguilar. Memorial Sloan Kettering Cancer Centre, New York
- 15.30-16.00h Discussion
- 16.00-16.05h **Conclusions and closure**